Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits

被引:27
作者
Burke, Brian [1 ]
Gomez-Roman, Victor Raul [1 ]
Lian, Ying [1 ]
Sun, Yide [1 ]
Kan, Elaine [1 ]
Ulmer, Jeffrey [1 ]
Srivastava, Indresh K. [1 ]
Barnett, Susan W. [1 ]
机构
[1] Novartis Vaccines & Diagnost, Emeryville, CA 94608 USA
关键词
HIV-1; Neutralization; Adjuvants; MF59; CpG; Multivalent; HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; POLYVALENT DNA PRIME; GM-CSF DNA; IMMUNE-RESPONSES; RHESUS MACAQUES; DENDRITIC CELLS; PARTIAL DELETION; HUMAN VOLUNTEERS; CLADE-A;
D O I
10.1016/j.virol.2009.02.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Improving the potency, breadth, and durability of neutralizing antibody responses to HIV are major challenges for HIV vaccine development. To address these challenges, the studies described evaluate in rabbits the titers, breadth, and epitope specificities of antibody responses elicited by HIV envelope subunit vaccines adjuvanted with MF59 with or without CpG oligodeoxynucleotide (ODN). Animals were immunized with trimeric o-gp140 Delta V2 derived from subtype B HIV-1(SF162) or subtype C HIV-1(TV1), or proteins from both strains. Immunization with SF162 or TV1 with MF59/CpG elicited higher titers of binding and neutralizing antibodies to SF162 than monovalent immunization with MF59 alone (P<0.01). Bivalent immunization increased binding and neutralizing antibody titers over single envelope immunization in MF59 (P<0.01). Bivalent immunization also improved neutralization breadth. Epitope mapping indicated neutralizing activity in rabbits was directed to V3 and V4. Overall, our data Suggests that a multivalent vaccination approach with MF59 and CpG can enhance humoral responses to HIV-1. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:147 / 156
页数:10
相关论文
共 50 条
[21]   Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B V3 domains are common in patient sera from cameroon, but their neutralization activity is usually restricted by epitope masking [J].
Krachmarov, C ;
Pinter, A ;
Honnen, WJ ;
Gorny, MK ;
Nyambi, PN ;
Zolla-Pazner, S ;
Kayman, SC .
JOURNAL OF VIROLOGY, 2005, 79 (02) :780-790
[22]   Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1 [J].
Krachmarov, C. P. ;
Honnen, W. J. ;
Kayman, S. C. ;
Gorny, M. K. ;
Zolla-Pazner, S. ;
Pinter, Abraham .
JOURNAL OF VIROLOGY, 2006, 80 (14) :7127-7135
[23]   GM-CSF DNA:: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine [J].
Lai, Lilin ;
Vodros, Dalma ;
Kozlowski, Pamela A. ;
Montefiori, David C. ;
Wilson, Robert L. ;
Akerstrom, Vicki L. ;
Chennareddi, Lakshmi ;
Yu, Tianwei ;
Kannanganat, Sunil ;
Ofielu, Lazarus ;
Villinger, Francois ;
Wyatt, Linda S. ;
Moss, Bernard ;
Amara, Rama Rao ;
Robinson, Harriet L. .
VIROLOGY, 2007, 369 (01) :153-167
[24]   Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies [J].
Li, M ;
Gao, F ;
Mascola, JR ;
Stamatatos, L ;
Polonis, VR ;
Koutsoukos, M ;
Voss, G ;
Goepfert, P ;
Gilbert, P ;
Greene, KM ;
Bilska, M ;
Kothe, DL ;
Salazar-Gonzalez, JF ;
Wei, XP ;
Decker, JM ;
Hahn, BH ;
Montefiori, DC .
JOURNAL OF VIROLOGY, 2005, 79 (16) :10108-10125
[25]   Evaluation of envelope Vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain [J].
Lian, Y ;
Srivastava, I ;
Gómez-Román, VR ;
zur Megede, J ;
Sun, YD ;
Kan, E ;
Hilt, S ;
Engelbrecht, S ;
Himathongkham, S ;
Luciw, PA ;
Otten, G ;
Ulmer, JB ;
Donnelly, JJ ;
Rabussay, D ;
Montefiori, D ;
van Rensburg, EJ ;
Barnett, SW .
JOURNAL OF VIROLOGY, 2005, 79 (21) :13338-13349
[26]   Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes [J].
Ljungberg, K ;
Rollman, E ;
Eriksson, L ;
Hinkula, J ;
Wahren, B .
VIROLOGY, 2002, 302 (01) :44-57
[27]  
Montefiori D., 2004, CURRENT PROTOCOLS IM, p12.11.11
[28]  
O'Hagan DT, 2002, VACCINE, V20, P3389
[29]  
Ott G, 1995, Pharm Biotechnol, V6, P277
[30]   Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate [J].
Pal, R ;
Wang, SX ;
Kalyanaraman, VS ;
Nair, BC ;
Whitney, S ;
Keen, T ;
Hocker, L ;
Hudacik, L ;
Rose, N ;
Cristillo, A ;
Mboudjeka, I ;
Shen, SY ;
Wu-Chou, TH ;
Montefiori, D ;
Mascola, J ;
Lu, S ;
Markham, P .
JOURNAL OF MEDICAL PRIMATOLOGY, 2005, 34 (5-6) :226-236